UBS Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $55

Benzinga Newsdesk www.benzinga.com Neutral 49.9%

Neg 0% Neu 49.9% Pos 0%

UBS analyst Michael Yee initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $55.